Sitagliptin Reduces Cardiac Apoptosis, Hypertrophy and Fibrosis Primarily by Insulin-Dependent Mechanisms in Experimental type-II Diabetes. Potential Roles of GLP-1 Isoforms

BACKGROUND: Myocardial fibrosis is a key process in diabetic cardiomyopathy. However, their underlying mechanisms have not been elucidated, leading to a lack of therapy. The glucagon-like peptide-1 (GLP-1) enhancer, sitagliptin, reduces hyperglycemia but may also trigger direct effects on the heart....

Descripción completa

Detalles Bibliográficos
Autores principales: Picatoste, Belén, Ramírez, Elisa, Caro-Vadillo, Alicia, Iborra, Cristian, Egido, Jesús, Tuñón, José, Lorenzo, Óscar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3840053/
https://www.ncbi.nlm.nih.gov/pubmed/24302978
http://dx.doi.org/10.1371/journal.pone.0078330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3840053/
https://www.ncbi.nlm.nih.gov/pubmed/24302978
http://dx.doi.org/10.1371/journal.pone.0078330

Ejemplares similares